1 |
Wang X, Chen Y, Xu M, Cheng K, Duan X, Liao W, Wang Y, Lu Y, Duan Z, Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34511012 DOI: 10.1080/17474124.2021.1980385] [Reference Citation Analysis]
|
2 |
Liu L, Xie S, Teng Y, Deng Z, Chen K, Liu H, Huo R, Liang X, Guo P, Yang D, Ma L, Xiang B, Li L, Zhong J. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol 2022;11:783339. [DOI: 10.3389/fonc.2021.783339] [Reference Citation Analysis]
|
3 |
Papatheodoridi M, Tampaki M, Lok AS, Papatheodoridis GV. Risk of HBV reactivation during therapies for HCC: A systematic review. Hepatology 2021. [PMID: 34918361 DOI: 10.1002/hep.32241] [Reference Citation Analysis]
|
4 |
Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
|